Amir Elstein - 15 Jun 2024 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
Director
Signature
/s/ Dov Bergwerk as attorney-in-fact for Amir Elstein
Issuer symbol
TEVA
Transactions as of
15 Jun 2024
Net transactions value
$0
Form type
4
Filing time
17 Jun 2024, 07:17:48 UTC
Previous filing
10 Jun 2024
Next filing
09 Jun 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TEVA Ordinary Shares Options Exercise +21,108 +1% 2,094,331 15 Jun 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Options Exercise $0 -21,108 -100% $0.000000* 0 15 Jun 2024 Ordinary Shares 21,108 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3 Restricted Share Units were granted on June 15, 2023 and vested on June 15, 2024.